Renal Dysfunction in Cirrhosis: Diagnosis, Treatment and Prevention

Overview

Journal MedGenMed

Specialty General Medicine

Date 2005 Mar 19

PMID 15775836

Citations 5

Authors

Elaine Yeung

Elaine Yong

Florence Wong

Affiliations

Soon will be listed here.

Citing Articles

Nephrotoxicity in cancer treatment: An update.

Chen C, Xie D, Gewirtz D, Li N Adv Cancer Res. 2022; 155:77-129.

PMID: 35779877 PMC: 11017963. DOI: 10.1016/bs.acr.2022.03.005.

Exercise and physical activity in cirrhosis: opportunities or perils.

Bellar A, Welch N, Dasarathy S J Appl Physiol (1985). 2020; 128(6):1547-1567.

PMID: 32240017 PMC: 7311690. DOI: 10.1152/japplphysiol.00798.2019.

The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis.

Kumar V, Dong Y, Kumar V, Almawash S, Mahato R Theranostics. 2019; 9(25):7537-7555.

PMID: 31695785 PMC: 6831471. DOI: 10.7150/thno.38913.

Vascular Doppler ultrasonographic indices in cirrhosis: a case-control study with emphasis on the common carotid arteries.

Shakeri A, Varshochi M, Atapour N, Nemati M, Khoshbaten M, Fouladi D Radiol Med. 2015; 120(10):982-8.

PMID: 25725791 DOI: 10.1007/s11547-015-0524-2.

Kidneys in chronic liver diseases.

Hartleb M, Gutkowski K World J Gastroenterol. 2012; 18(24):3035-49.

PMID: 22791939 PMC: 3386317. DOI: 10.3748/wjg.v18.i24.3035.

References

Wong F, Massie D, Colman J, Dudley F . Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology. 1993; 104(3):884-9. DOI: 10.1016/0016-5085(93)91026-e. View

Sanyal A, FREEDMAN A, Shiffman M, Purdum 3rd P, Luketic V, Cheatham A . Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology. 1994; 20(1 Pt 1):46-55. DOI: 10.1016/0270-9139(94)90133-3. View

Arroyo V, Guevara M, Gines P . Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 2002; 122(6):1658-76. DOI: 10.1053/gast.2002.33575. View

Albillos A, Banares R, del Arbol L, Moitinho E, Rodriguez C, Gonzalez M . Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001; 121(2):382-8. DOI: 10.1053/gast.2001.26288. View

Mitzner S, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J . Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher. 2002; 5(5):417-22. DOI: 10.1046/j.1526-0968.2001.00388.x. View

Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Zozaya J . Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology. 1995; 21(4):986-94. View

Bacq Y, Gaudin C, Hadengue A, Roulot D, Braillon A, Moreau R . Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology. 1991; 14(3):483-7. View

Angeli P, Jimenez W, Arroyo V, Mackenzie H, Zhang P, Claria J . Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology. 1994; 20(4 Pt 1):948-54. DOI: 10.1002/hep.1840200425. View

Ros J, Claria J, Jimenez W, Bosch-Marce M, Angeli P, Arroyo V . Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology. 1995; 22(3):915-20. View

10.

Salerno F, Del Bo A, Maggi A, Marabini M, Maffi M, Borroni G . Vasopressin release and water metabolism in patients with cirrhosis. J Hepatol. 1994; 21(5):822-30. DOI: 10.1016/s0168-8278(94)80245-9. View

11.

Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B . Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999; 353(9149):294-5. DOI: 10.1016/s0140-6736(05)74933-3. View

12.

Dagher L, Moore K . The hepatorenal syndrome. Gut. 2001; 49(5):729-37. PMC: 1728492. DOI: 10.1136/gut.49.5.729. View

13.

Arroyo V, Camps J, Rimola A, Gaya J, Costa J, Rivera F . Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int. 1984; 26(1):72-80. DOI: 10.1038/ki.1984.136. View

14.

Pomier-Layrargues G, Paquin S, Hassoun Z, Lafortune M, Tran A . Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003; 38(1):238-43. DOI: 10.1053/jhep.2003.50276. View

15.

Brensing K, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H . Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000; 47(2):288-95. PMC: 1727992. DOI: 10.1136/gut.47.2.288. View

16.

Gines P, Guevara M, Arroyo V, Rodes J . Hepatorenal syndrome. Lancet. 2003; 362(9398):1819-27. DOI: 10.1016/S0140-6736(03)14903-3. View

17.

Lake J, Ring E, Laberge J, Gordon R, Roberts J, Ascher N . Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc. 1993; 25(2):1766-7. View

18.

Arroyo V, Colmenero J . Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003; 38 Suppl 1:S69-89. DOI: 10.1016/s0168-8278(03)00007-2. View

19.

Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D . Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut. 1986; 27(10):1204-9. PMC: 1433865. DOI: 10.1136/gut.27.10.1204. View

20.

Lenz K, Hortnagl H, Druml W, Grimm G, Laggner A, Schneeweisz B . Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut. 1989; 30(1):90-6. PMC: 1378237. DOI: 10.1136/gut.30.1.90. View